BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38041219)

  • 1. Cold atmospheric plasma sensitizes melanoma cells to targeted therapy agents in vitro.
    Yan C; Zhao L; Zhang X; Chu Z; Zhou T; Zhang Y; Geng S; Guo K
    J Biophotonics; 2024 Mar; 17(3):e202300356. PubMed ID: 38041219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosafety and differentially expressed genes analysis of melanoma cells treated with cold atmospheric plasma.
    Zhao L; Yan C; Kong S; Jia T; Chu Z; Yang L; Wu J; Geng S; Guo K
    J Biophotonics; 2022 Jun; 15(6):e202100403. PubMed ID: 35261164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
    Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU
    Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways.
    Candido S; Salemi R; Piccinin S; Falzone L; Libra M
    Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
    Kakadia S; Yarlagadda N; Awad R; Kundranda M; Niu J; Naraev B; Mina L; Dragovich T; Gimbel M; Mahmoud F
    Onco Targets Ther; 2018; 11():7095-7107. PubMed ID: 30410366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cold atmospheric plasma induces apoptosis of melanoma cells via Sestrin2-mediated nitric oxide synthase signaling.
    Xia J; Zeng W; Xia Y; Wang B; Xu D; Liu D; Kong MG; Dong Y
    J Biophotonics; 2019 Jan; 12(1):e201800046. PubMed ID: 29931745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
    Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
    Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
    Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
    Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cold atmospheric pressure plasma treatment combined with starvation increases autophagy and apoptosis in melanoma in vitro and in vivo.
    Golpour M; Alimohammadi M; Sohbatzadeh F; Fattahi S; Bekeschus S; Rafiei A
    Exp Dermatol; 2022 Jul; 31(7):1016-1028. PubMed ID: 35181947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma.
    Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
    Mol Ther Oncolytics; 2020 Sep; 18():100-108. PubMed ID: 32637584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.
    Fattore L; Marra E; Pisanu ME; Noto A; de Vitis C; Belleudi F; Aurisicchio L; Mancini R; Torrisi MR; Ascierto PA; Ciliberto G
    J Transl Med; 2013 Jul; 11():180. PubMed ID: 23890105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma.
    Wang M; Geilich BM; Keidar M; Webster TJ
    Int J Nanomedicine; 2017; 12():4117-4127. PubMed ID: 28615940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
    Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
    Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Effect of Cold Atmospheric Plasma in Syngeneic Mouse Models of Melanoma and Colon Cancer.
    Jung JM; Yoon HK; Kim SY; Yun MR; Kim GH; Lee WJ; Lee MW; Chang SE; Won CH
    Molecules; 2023 May; 28(10):. PubMed ID: 37241912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
    Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
    Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF in malignant melanoma progression and metastasis: potentials and challenges.
    Alqathama A
    Am J Cancer Res; 2020; 10(4):1103-1114. PubMed ID: 32368388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study.
    Pópulo H; Domingues B; Sampaio C; Lopes JM; Soares P
    J Exp Pharmacol; 2021; 13():521-535. PubMed ID: 34079392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.